Antibody therapeutics for Ebola virus disease

Current Opinion in Virology

Volumn 17, Issue , 2016, Pages 45-49

  Zeitlin, Larry ^a   Whaley, Kevin J ^a   Olinger, Gene G ^b   Jacobs, Michael ^c   Gopal, Robin ^d   Qiu, Xiangguo ^e,f   Kobinger, Gary P ^e,f  

^a Mapp Biopharmaceutical Inc   (United States)

^b Integrated Research Facility   (United States)

^c ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^f UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

AFRICA; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; HUMAN; NONHUMAN; PASSIVE IMMUNIZATION; PRIMATE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; ANIMAL; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; MACACA; PROCEDURES; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE OUTBREAKS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNIZATION, PASSIVE; MACACA; PRIMATES; VIRAL LOAD;

EID: 84961294250     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.01.006     Document Type: Review

References (30)

1. A. Casadevall, and M.D. Scharff Return to the past: the case for antibody-based therapies in infectious diseases Clin Infect Dis 21 1995 150 161
2. L. Zeitlin, R.A. Cone, T.R. Moench, and K.J. Whaley Preventing infectious disease with passive immunization Microbes Infect 2 2000 701 708
3. L. Zeitlin, R.A. Cone, and K.J. Whaley Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases Emerg Infect Dis 5 1999 54 64
4. J.M. Reichert Trends in the development and approval of monoclonal antibodies for viral infections BioDrugs 21 2007 1 7
5. J.M. Reichert, C.J. Rosensweig, L.B. Faden, and M.C. Dewitz Monoclonal antibody successes in the clinic Nat Biotechnol 23 2005 1073 1078
6. K. Mupapa, M. Massamba, K. Kibadi, K. Kuvula, A. Bwaka, M. Kipasa, R. Colebunders, and J.J. Muyembe-Tamfum Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients J Infect Dis 179 1999 S18 S23
7. P.B. Jahrling, J.B. Geisbert, J.R. Swearengen, T. Larsen, and T.W. Geisbert Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates J Infect Dis 196 2007 S400 S403
8. N.M. Kudoyarova-Zubavichene, N.N. Sergeyev, A.A. Chepurnov, and S.V. Netesov Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections J Infect Dis 179 1999 S218 S223
9. P.B. Jahrling, J. Geisbert, J.R. Swearengen, G.P. Jaax, T. Lewis, J.W. Huggins, J.J. Schmidt, J.W. LeDuc, and C.J. Peters Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses Arch Virol Suppl 11 1996 135 140
10. P.B.G.T. Jahrling, J.B. Geisbert, J.R. Swearengen, M. Bray, N.K. Jaax, J.W.L.J. Huggins, and C.J. Peters Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections J Infect Dis 179 1999 11
11. T. Maruyama, L.L. Rodriguez, P.B. Jahrling, A. Sanchez, A.S. Khan, S.T. Nichol, C.J. Peters, P.W. Parren, and D.R. Burton Ebola virus can be effectively neutralized by antibody produced in natural human infection J Virol 73 1999 6024 6030
12. P.W. Parren, T.W. Geisbert, T. Maruyama, P.B. Jahrling, and D.R. Burton Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody J Virol 76 2002 6408 6412
13. W.B. Oswald, T.W. Geisbert, K.J. Davis, J.B. Geisbert, N.J. Sullivan, P.B. Jahrling, P.W. Parren, and D.R. Burton Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys PLoS Pathog 3 2007 e9
14. J.M. Dye, A.S. Herbert, A.I. Kuehne, J.F. Barth, M.A. Muhammad, S.E. Zak, R.A. Ortiz, L.I. Prugar, and W.D. Pratt Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease Proc Natl Acad Sci 109 2012 5034 5039
15. A. Marzi, R. Yoshida, H. Miyamoto, M. Ishijima, Y. Suzuki, M. Higuchi, Y. Matsuyama, M. Igarashi, E. Nakayama, M. Kuroda, and et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever PLoS One 7 2012 e36192
16. X. Qiu, J. Audet, G. Wong, S. Pillet, A. Bello, T. Cabral, J.E. Strong, F. Plummer, C.R. Corbett, J.B. Alimonti, and et al. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies Sci Transl Med 4 2012 138ra181
17. G.G. Olinger Jr., J. Pettitt, D. Kim, C. Working, O. Bohorov, B. Bratcher, E. Hiatt, S.D. Hume, A.K. Johnson, J. Morton, and et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques Proc Natl Acad Sci U S A 109 2012 18030 18035
18. L. Zeitlin, J. Pettitt, C. Scully, N. Bohorova, D. Kim, M. Pauly, A. Hiatt, L. Ngo, H. Steinkellner, K.J. Whaley, and et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant Proc Natl Acad Sci 108 2011 20690 20694
19. J. Pettitt, L. Zeitlin, H. Kim do, C. Working, J.C. Johnson, O. Bohorov, B. Bratcher, E. Hiatt, S.D. Hume, A.K. Johnson, and et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail Sci Transl Med 5 2013 199ra113
20. X. Qiu, G. Wong, J. Audet, A. Bello, L. Fernando, J.B. Alimonti, H. Fausther-Bovendo, H. Wei, J. Aviles, E. Hiatt, and et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp Nature 514 2014 47 53
21. WHO Ethical considerations for use of unregistered interventions for Ebola virus disease 2014
22. M. Lanari, T. Lazzarotto, V. Venturi, I. Papa, L. Gabrielli, B. Guerra, M.P. Landini, and G. Faldella Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns Pediatrics 117 2006 e76 e83
23. O. Ramilo, R. Lagos, X. Saez-Llorens, J. Suzich, C.K. Wang, K.M. Jensen, B.S. Harris, G.A. Losonsky, and M.P. Griffin Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness Pediatr Infect Dis J 33 2014 703 709
24. J.K.M.A. Sarkar, M.K. Mukherjee, S.K. De, and D.G. Mazumdar Virus excretion in smallpox. 1. Excretion in the throat, urine, and conjunctiva of patients Bull World Health Organ 48 1973 517 522
25. G. Fitzpatrick, F. Vogt, O.B. Moi Gbabai, T. Decroo, M. Keane, H. De Clerck, A. Grolla, R. Brechard, K. Stinson, and M. Van Herp The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Medecins Sans Frontieres Ebola Case Management Centre, Kailahun, Sierra Leone, June-October 2014 J Infect Dis 2015
26. N.J. Sullivan, J.E. Martin, B.S. Graham, and G.J. Nabel Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule Nat Rev Microbiol 7 2009 393 400
27. A. Takada, H. Ebihara, S. Jones, H. Feldmann, and Y. Kawaoka Protective efficacy of neutralizing antibodies against Ebola virus infection Vaccine 25 2007 993 999
28. G. Wong, J.S. Richardson, S. Pillet, A. Patel, X. Qiu, J. Alimonti, J. Hogan, Y. Zhang, A. Takada, H. Feldmann, and et al. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates Sci Transl Med 4 2012 158ra146
29. E. Cox, L. Borio, and R. Temple Evaluating Ebola therapies - the case for RCTs N Engl J Med 371 2014 2350 2351
30. R.E. Biagini, W.J. Moorman, J.B. Lal, J.S. Gallagher, and I.L. Bernstein Normal serum IgE and IgG antibody levels in adult male cynomolgus monkeys Lab Anim Sci 38 1988 194 196